Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part A: Placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

NCT05529849
View directory record Official record
Conditions
Cachexia
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males

NCT01514578
View directory record Official record
Conditions
Healthy
Interventions
TRV130A, Dextrose in Water
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
19 Years to 50 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 28, 2026, 3:04 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

NCT02951195
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-152, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

NCT07566130
View directory record Official record
Conditions
Healthy Volunteers
Interventions
nacresertib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT07229911
View directory record Official record
Conditions
Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions
TAK-781, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

NCT07377539
View directory record Official record
Conditions
Healthy Participants
Interventions
JZP047, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

NCT02527200
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Santa Monica, California • Baltimore, Maryland • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 28, 2026, 3:04 PM EDT
Recruiting Early Phase 1 Interventional

VTP-1000 in Adults With Celiac Disease

NCT06310291
View directory record Official record
Conditions
Celiac Disease
Interventions
VTP-1000, Matched Placebo
Biological · Other
Lead sponsor
Barinthus Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Colorado Springs, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 28, 2026, 3:04 PM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

NCT01368926
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 3:04 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2010 · Synced Sep 28, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

NCT01657877
View directory record Official record
Conditions
Caries
Interventions
Calcium sodium phosphosilicate, Sodium monoflurophosphate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 28, 2026, 3:04 PM EDT
Active, not recruiting Phase 1 Interventional

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-0151, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Anniston, Alabama • La Jolla, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 3:04 PM EDT